NEAT1 in Ovarian Cancer: A Key Regulator of Tumor Progression, Follicular Fluid Dynamics, and Therapeutic Resistance.

IF 1.6 4区医学 Q4 ONCOLOGY

Anticancer research Pub Date : 2025-03-01 DOI:10.21873/anticanres.17472

Yun-Chieh Wu, Min-Hsi Ku, Wei-Lun Huang, Luiza Dias, Chi-Wei Chen

{"title":"NEAT1 in Ovarian Cancer: A Key Regulator of Tumor Progression, Follicular Fluid Dynamics, and Therapeutic Resistance.","authors":"Yun-Chieh Wu, Min-Hsi Ku, Wei-Lun Huang, Luiza Dias, Chi-Wei Chen","doi":"10.21873/anticanres.17472","DOIUrl":null,"url":null,"abstract":"<p><p>Nuclear enriched abundant transcript 1 (NEAT1), a long non-coding RNA (lncRNA), is a critical player in the pathogenesis and progression of ovarian cancer. Its abnormal expression in patients' follicular fluid (FF), granulosa cells, and oocytes has been linked to key processes such as cell proliferation, apoptosis, nuclear maturation, and follicle development. NEAT1's regulation of oocyte maturation and its influence on tumor dynamics and cellular communication within the FF is well-established. In the ovarian tumor microenvironment, NEAT1 contributes to cellular proliferation, invasion, chemoresistance, and apoptosis. Moreover, its dysregulation correlates with poor prognosis and increased tumor aggressiveness, underscoring its potential as a therapeutic target. The interaction of NEAT1 with miRNAs and signaling pathways further highlights its significant role in ovarian cancer progression and its potential as a biomarker. This review explores NEAT1's contributions to ovarian cancer progression, its influence within the follicular fluid microenvironment, and its therapeutic potential as a target to combat ovarian cancer development and drug resistance.</p>","PeriodicalId":8072,"journal":{"name":"Anticancer research","volume":"45 3","pages":"825-842"},"PeriodicalIF":1.6000,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Anticancer research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.21873/anticanres.17472","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Nuclear enriched abundant transcript 1 (NEAT1), a long non-coding RNA (lncRNA), is a critical player in the pathogenesis and progression of ovarian cancer. Its abnormal expression in patients' follicular fluid (FF), granulosa cells, and oocytes has been linked to key processes such as cell proliferation, apoptosis, nuclear maturation, and follicle development. NEAT1's regulation of oocyte maturation and its influence on tumor dynamics and cellular communication within the FF is well-established. In the ovarian tumor microenvironment, NEAT1 contributes to cellular proliferation, invasion, chemoresistance, and apoptosis. Moreover, its dysregulation correlates with poor prognosis and increased tumor aggressiveness, underscoring its potential as a therapeutic target. The interaction of NEAT1 with miRNAs and signaling pathways further highlights its significant role in ovarian cancer progression and its potential as a biomarker. This review explores NEAT1's contributions to ovarian cancer progression, its influence within the follicular fluid microenvironment, and its therapeutic potential as a target to combat ovarian cancer development and drug resistance.

查看原文本刊更多论文

求助全文

约1分钟内获得全文求助全文

来源期刊

Anticancer research 医学-肿瘤学

CiteScore

3.70

自引率

10.00%

发文量

566

审稿时长

2 months

期刊介绍： ANTICANCER RESEARCH is an independent international peer-reviewed journal devoted to the rapid publication of high quality original articles and reviews on all aspects of experimental and clinical oncology. Prompt evaluation of all submitted articles in confidence and rapid publication within 1-2 months of acceptance are guaranteed. ANTICANCER RESEARCH was established in 1981 and is published monthly (bimonthly until the end of 2008). Each annual volume contains twelve issues and index. Each issue may be divided into three parts (A: Reviews, B: Experimental studies, and C: Clinical and Epidemiological studies). Special issues, presenting the proceedings of meetings or groups of papers on topics of significant progress, will also be included in each volume. There is no limitation to the number of pages per issue.